Skip to content
Catalyst

knowcompoundsazithromycin

Specimen compound organic compoundPlate I

Azithromycin

A dial of hairlines, each a peak of azithromycin's measured mass spectrum, its angle the peak's mass-to-charge ratio and its length the peak's intensity.
fig. 1Azithromycin · MS2 [M+H]+ LC-ESI-QFT positive · MassBank MSBNK-ACES_SU-AS000715 (ACESx, CC BY)
Formula
C38H72N2O12
Molar mass
748.996 g/mol
InChIKey
MQTOSJVFKKJCRP-BICOPXKESA-N

– no difference found

01 · the evidence, ordered

What the evidence says

Fig. 2 Azithromycin CHEBI:2955 2 endpoints 2 findings
×1.60
Labels
CompoundInspector

Azithromycin

36 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

02 · findings

What azithromycin moved, and by how much

  • MD mean difference · OR odds ratio. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
  1. Duration of mechanical ventilationMoved: no difference foundEffect, as reportedMD0.13[−1.35 to 1.6]Evidence: Very limitedPaper: PMID 407958092026
    Who
    preterm infants (meta-analysis of 6 RCTs, 1,360 infants; azithromycin vs placebo, whole population not restricted by Ureaplasma status)
    Dose studied
    not reported

    The composite of BPD or death (RR: 0.95; 95% CI: 0.83-1.10; p = 0.53; I2 = 50.2%), BPD (RR: 0.98; 95% CI: 0.83-1.15; p = 0.77; I2 = 38.1%), death (RR: 0.88; 95% CI: 0.66-1.19; p = 0.41; I2 = 0%), NEC (RR: 0.94; 95% CI: 0.69-1.26; p = 0.67; I2 = 0%), IVH (RR: 1.22; 95% CI: 0.89-1.68; p = 0.22; I2 = 3.5%), RoP (RR: 1.35; 95% CI: 0.43-4.28; p = 0.61; I2 = 76.3%), duration of mechanical ventilation (MD: 0.13; 95% CI: -1.35 to 1.60; p = 0.87; I2 = 0%), and postnatal corticosteroid requirement (RR: 0.84; 95% CI: 0.64-1.08; p = 0.18; I2 = 34.5%) were similar between the groups.”

    Quoted verbatim from Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis.meta-analysisPermalink
  2. All-cause mortalityMoved: no difference foundEffect, as reportedOR0.96[0.88 to 1.05]Evidence: Very limitedPaper: PMID 340776002022
    Who
    Patients with Covid-19; seven randomized trials, 8822 patients in total, azithromycin versus standard of care
    Dose studied
    not reported

    The use of AZM was not associated with mortality in Covid-19 patients (OR = 0.96, 95% CI 0.88-1.05, p = 0.317 based on the random-effect meta-analysis).”

    Quoted verbatim from Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials.meta-analysisPermalink

No dose is advised.

  • MD mean difference · OR odds ratio. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed

03 · identity

Structure

fig. 3Azithromycin · 2D structure · ChEBI’s SMILES
Charge
0
SMILES
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O

04 · the record

Sources

1,268

papers screened for azithromycin

admitted
3
read and discarded
100
not read yet
1,165

The screening record, every paper and why

Documented interactions
None reported

Sources cited

2 papers · 2 findings

1 admitted at screening, no finding yet

Show every paper citedHide the papers cited